Reinforced cementoplasty using dedicated spindles in the management of unstable malignant lesions of the cervicotrochanteric region. Premat K et al. Eur Radiol. 2017 Mar 13. doi: 10.1007/s00330-017-4774-3. [Epub ahead of print]. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study. Losem C et al. Onco Targets Ther. 2017 Feb…
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. Sidana S et al. PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017. Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge? El-Jurdi N et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.20. [Epub ahead of print]. Long-term control of extensive refractory chronic…
Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. Tuchman SA et al. J Geriatr Oncol. 2017 Feb 27. pii: S1879-4068(17)30030-9. doi: 10.1016/j.jgo.2017.02.004. [Epub ahead of print]. Carfilzomib containing combinations as frontline therapy for multiple myeloma: a meta analysis of 13 trials. Sheng Z et al. Eur J Haematol. 2017…
Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Howell D et al. Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14513. [Epub ahead of print]. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. Lisenko K et al. BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4. Association between response rates…
Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Palmaro A et al. Pharmacoepidemiol Drug Saf. 2017 Feb 15. doi: 10.1002/pds.4180. [Epub ahead of print]. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Cho YK et al. Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.644. [Epub…
Renal failure in multiple myeloma: something new on the horizon. Offidani M et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14548. [Epub ahead of print]. Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients. Vázquez L et al. Rev Esp Quimioter. 2017 Feb 14. pii: vazquez14feb2017. [Epub ahead of print]. Myelosuppression-sparing treatment of central nervous…
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Berdeja JG et al. Br J Haematol. 2017 Feb 7. doi: 10.1111/bjh.14536. [Epub ahead of print]. Impact of induction treatment before autologous stem cell transplantation on long term outcome in patients with newly diagnosed multiple…
Results of a meta-regression analysis have shown that, contrary to popular opinion, there is no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in newly diagnosed myeloma patients. Published recently in the European Journal of Haematology, the researchers explored the relationship between response to initial…
Myeloma UK together with the British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) have jointly published new guidelines for the screening and management of the late and long-term consequences of myeloma and its treatments. Published recently in the British Journal of Haematology, the guidelines highlight the key late effects…
Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Kapoor P et al. Nat Rev Clin Oncol. 2017 Feb;14(2):73-74. doi: 10.1038/nrclinonc.2016.221. Epub 2017 Jan 10. Trends in overall survival and costs of multiple myeloma, 2000-2014. Fonseca R et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.380. [Epub ahead of print]. Current treatment options of T cell-associated immunotherapy in multiple myeloma. Liu H et…